UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA
Clinical trials for UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo for bile duct cancer shows promise in tiny trial
Disease control CompletedThis phase 2 study tested a combination of two drugs, durvalumab and SNDX-6352, in 5 people with advanced bile duct cancer that had not spread beyond the liver. Participants first received standard chemo or radiation therapy directly into the liver, then the drug combination. The…
Matched conditions: UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Triple chemo attack shows promise against tough bile duct cancers
Disease control CompletedThis phase III trial tested whether adding nab-paclitaxel to the standard two-drug chemo (gemcitabine and cisplatin) helps people with newly diagnosed, advanced biliary tract cancers live longer. Over 450 patients took part. The goal is to see if the three-drug combo improves ove…
Matched conditions: UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New cocktail of drugs shows early promise against tough bile duct cancer
Disease control CompletedThis phase 2 trial tested a combination of three drugs—chemotherapy delivered directly to the liver, a targeted pill, and an immunotherapy—in 25 people with advanced bile duct cancer that could not be removed surgically. The goal was to see if the combination could shrink tumors …
Matched conditions: UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC